Heart Failure (HF) - Disease Information

Overview

Heart failure is a complex clinical syndrome characterized by structural or functional impairment of ventricular filling or ejection of blood, resulting in the inability of the heart to pump blood at a rate commensurate with the body's metabolic needs.

Epidemiology: Heart failure affects approximately 64 million people worldwide, with a prevalence of 1-2% in developed countries. The incidence doubles with each decade of life after age 45. Despite advances in treatment, 5-year mortality remains high at 50%, worse than many cancers. Annual healthcare costs exceed $30 billion in the United States alone.

Classification & Staging

NYHA Functional Classification:

Class	Description	Annual Mortality	Clinical Features
Class I	No limitation of physical activity	5-10%	Asymptomatic at rest and with ordinary activity
Class II	Slight limitation of physical activity	10-15%	Comfortable at rest, symptoms with ordinary activity
Class III	Marked limitation of physical activity	15-20%	Comfortable at rest, symptoms with minimal activity
Class IV	Unable to carry on any physical activity	30-50%	Symptoms at rest, any activity increases discomfort

ACC/AHA Stages of Heart Failure:

Stage	Definition	Therapy Goals	5-Year Mortality
Stage A	At high risk but no structural disease	Risk factor modification	5-10%
Stage B	Structural heart disease but no symptoms	Prevent progression	15-20%
Stage C	Structural disease with prior or current symptoms	Reduce symptoms, hospitalizations	25-35%
Stage D	Refractory symptoms despite maximal therapy	Palliative care, advanced therapies	50-75%

Etiology & Pathophysiology

Major Etiologies:

Category	Specific Causes	Frequency	Mechanism
Ischemic	Coronary artery disease, myocardial infarction	60-70%	Myocyte loss, remodeling
Hypertensive	Long-standing hypertension	10-15%	Pressure overload, hypertrophy
Valvular	Aortic stenosis, mitral regurgitation	5-10%	Volume/pressure overload
Cardiomyopathic	Dilated, hypertrophic, restrictive CM	5-10%	Primary myocardial disease
Other	Myocarditis, congenital, arrhythmias	5-10%	Variable mechanisms

Neurohormonal Activation in HF:

System	Key Mediators	Effects	Therapeutic Targets
Sympathetic Nervous System	Norepinephrine, Epinephrine	Vasoconstriction, tachycardia, remodeling	Beta-blockers
Renin-Angiotensin-Aldosterone	Angiotensin II, Aldosterone	Vasoconstriction, sodium retention, fibrosis	ACEi, ARB, ARNI, MRA
Natriuretic Peptides	ANP, BNP	Vasodilation, natriuresis, counter-regulation	Neprilysin inhibitors
Vasopressin System	ADH	Water retention, vasoconstriction	Vaptans

Clinical Presentation

Common Symptoms:

Dyspnea: Exertional, orthopnea, paroxysmal nocturnal dyspnea
Fatigue and Weakness: Due to reduced cardiac output
Fluid Retention: Peripheral edema, ascites, weight gain
Reduced Exercise Tolerance: Early fatigue with daily activities
Nocturnal Cough: Often misdiagnosed as asthma or bronchitis

Physical Examination Findings:

System	Findings	Sensitivity	Specificity
Cardiac	S3 gallop, displaced PMI, murmurs	30-40%	90-95%
Pulmonary	Rales, wheezing, decreased breath sounds	50-60%	70-80%
Volume Status	JVD, hepatojugular reflux, edema	40-50%	80-90%
Perfusion	Cool extremities, delayed capillary refill	30-40%	85-90%

Acute Decompensated Heart Failure Red Flags: Resting dyspnea, oxygen saturation <90%, systolic BP <90 mmHg, altered mental status, cold clammy skin, anuria. Require immediate hospitalization.

Diagnosis & Investigations

Essential Diagnostic Tests:

Test	Purpose	Key Findings	Clinical Utility
BNP/NT-proBNP	Diagnosis, prognosis	Elevated levels correlate with severity	Rule out HF if normal
Echocardiogram	Assess structure and function	EF, wall motion, valves, dimensions	Essential for classification
ECG	Identify underlying causes	MI, LVH, arrhythmias, conduction disease	Universal screening
Chest X-ray	Assess pulmonary congestion	Cardiomegaly, pulmonary edema, effusions	Quick assessment of volume status
Basic Metabolic Panel	Evaluate electrolytes, renal function	Hyponatremia, renal impairment	Guide therapy, prognosis

Ejection Fraction Classification:

Category	LVEF Range	Prevalence	Therapeutic Approach
HFrEF	≤40%	50-60%	GDMT with proven mortality benefit
HFmrEF	41-49%	10-20%	Some benefit from HFrEF therapies
HFpEF	≥50%	30-40%	Symptom management, comorbidity control

Treatment & Management

Guideline-Directed Medical Therapy (GDMT) for HFrEF:

Medication Class	Examples	Mortality Reduction	Hospitalization Reduction
Beta-blockers	Bisoprolol, Carvedilol, Metoprolol	30-35%	30-40%
ACE Inhibitors	Lisinopril, Enalapril, Ramipril	20-25%	25-30%
ARB	Valsartan, Candesartan, Losartan	15-20%	20-25%
ARNI	Sacubitril/Valsartan	20% vs enalapril	21% vs enalapril
MRA	Spironolactone, Eplerenone	30%	35%
SGLT2 inhibitors	Empagliflozin, Dapagliflozin	25-30%	30-35%

Device Therapy Indications:

Device	Indication	Mortality Reduction	Patient Selection
ICD	Primary prevention in HFrEF	23%	LVEF ≤35%, NYHA II-III, >40 days post-MI
CRT	Cardiac resynchronization therapy	25-30%	LVEF ≤35%, LBBB, QRS ≥150ms
LVAD	Destination therapy	50% at 2 years	Stage D HF, inotrope-dependent

Ayurvedic Treatment

Ayurvedic Perspective:

Heart failure is understood as Hridroga progressing to Hridyashotha (cardiac edema) with involvement of all three doshas. The condition represents Rasavaha and Raktavaha Srotas Dushti leading to impaired nutrient delivery and fluid accumulation due to Vyana Vata dysfunction.

Herbal Formulations:

Arjunarishta: Primary cardiotonic and anti-failure formulation
Punarnavadi Guggulu: For edema and fluid retention
Chandraprabha Vati: Comprehensive metabolic support
Hridayarnava Rasa: For advanced heart failure with weakness
Pushkaramoolasava: For associated respiratory symptoms
Triphala Guggulu: For detoxification and metabolic balance

Single Herbs:

Herb	Sanskrit Name	Properties	Specific Benefits for HF
Arjuna	Arjuna (Terminalia arjuna)	Cardiotonic, inotropic, diuretic	Improves contractility, reduces edema, antioxidant
Punarnava	Punarnavā (Boerhavia diffusa)	Diuretic, anti-inflammatory, cardiotonic	Reduces edema, improves renal function, mild inotrope
Guggulu	Guggulu (Commiphora mukul)	Anti-inflammatory, lipid-lowering, rejuvenative	Reduces inflammation, improves endothelial function
Ashwagandha	Aśvagandhā (Withania somnifera)	Adaptogen, cardiotonic, anti-stress	Improves exercise tolerance, reduces fatigue
Gokshura	Gokshura (Tribulus terrestris)	Diuretic, cardiotonic, rejuvenative	Mild diuresis, supports renal function
Shilajit	Shilājit (Asphaltum)	Rejuvenative, adaptogen, mineral-rich	Improves energy, supports mitochondrial function
Brahmi	Brahmi (Bacopa monnieri)	Adaptogen, neuroprotective, diuretic	Reduces anxiety, mild diuretic effect
Garlic	Laśuna (Allium sativum)	Cardioprotective, hypotensive, diuretic	Lowers BP, mild diuresis, antioxidant

Ayurvedic Procedures:

Hrid Basti: Localized oil retention therapy
- Warm medicated oils (Mahanarayan, Dhanwantaram)
- Duration: 30-45 minutes daily
- Benefits: Improves coronary circulation, strengthens heart muscle
- Contraindications: Acute pulmonary edema, unstable patients
Virechana (Therapeutic Purgation):
- For Pitta and Kapha predominant heart failure
- Removes metabolic toxins and excess fluid
- Best performed in stable NYHA I-II patients
- Contraindicated in advanced heart failure, renal impairment
Basti (Medicated Enema):
- For Vata predominant heart failure
- Nourishing Basti for tissue strength
- Improves overall vitality and energy
- Caution in fluid-overloaded patients
Shirodhara: Continuous oil stream on forehead
- Reduces sympathetic overactivity
- Improves sleep quality and stress response
- Particularly beneficial for anxiety in heart failure
Udvartana: Herbal powder massage
- For Kapha predominant heart failure with obesity
- Improves circulation and metabolism
- Reduces edema and fluid retention

Dietary Recommendations (Ahara):

Recommended Foods:
- Light, easily digestible foods (moong dal, vegetable soups)
- Whole grains (barley, old rice, oats)
- Fresh fruits (pomegranate, apples, berries)
- Vegetables (bottle gourd, ridge gourd, leafy greens)
- Lean proteins (legumes, fish in moderation)
- Healthy fats (ghee in small quantities, olive oil)
Foods to Avoid:
- High sodium foods (pickles, processed foods, canned goods)
- Heavy, fried, and fatty foods
- Red meat and excessive animal protein
- Excess fluids (individualized restriction)
- Alcohol, tobacco, caffeine
- Cold drinks and ice cream
Special Recommendations:
- Arjuna bark decoction twice daily (1-3g in water)
- Punarnava decoction for edema management
- Garlic preparations for blood pressure control
- Small, frequent meals to avoid gastric pressure on heart
- Fluid restriction based on individual needs

Lifestyle Modifications (Vihara):

Physical Activity:
- Regular moderate exercise as tolerated (walking, cycling)
- Yoga asanas: Tadasana, Vajrasana, gentle backbends
- Pranayama: Anulom Vilom, Bhramari, Sheetali
- Avoid strenuous exercise and isometric activities
- Gradual warm-up and cool-down periods
Daily Routine (Dinacharya):
- Early morning waking and elimination
- Regular meal times (avoid heavy dinners)
- Adequate rest and sleep (7-8 hours with head elevation)
- Oil massage with mild oils (coconut, sesame)
- Stress management techniques
Stress Management:
- Regular meditation and mindfulness practice
- Relaxation techniques and deep breathing
- Adequate leisure and recreational activities
- Positive social interactions and support systems
- Avoid emotional stressors and conflicts
Seasonal Regimen (Ritucharya):
- Light diet in summer, warm in winter
- Avoid extreme temperatures and sudden changes
- Protect from cold winds and direct heat
- Regular monitoring during seasonal transitions

Ayurvedic Management Strategy: Comprehensive approach includes Nidana Parivarjana (avoidance of causative factors), Shodhana (purification therapies) for toxin elimination and fluid balance, Shamana (palliative treatments) for symptom relief and cardiac support, Brimhana (nourishing therapies) for tissue strength in advanced cases, Rasayana (rejuvenation therapies) for myocardial protection and prevention of progression, and strict Pathya-Apathya (dietary and lifestyle regulations) tailored to individual constitution and disease stage.

Complications

Common Complications:

Complication	Frequency	Risk Factors	Management
Cardiorenal Syndrome	25-40%	Diabetes, hypertension, advanced age	Careful diuresis, ultrafiltration
Cardiac Cachexia	15-20%	Advanced HF, chronic inflammation	Nutritional support, appetite stimulants
Thromboembolism	2-4% annually	Low EF, atrial fibrillation, immobility	Anticoagulation if indicated
Arrhythmias	50-80%	Low EF, electrolyte imbalance, ischemia	Antiarrhythmics, devices
Hepatic Congestion	10-15%	Right heart failure, tricuspid regurgitation	Diuresis, treat underlying cause

Prognosis & Risk Stratification

Mortality Predictors:

Predictor	Hazard Ratio	Clinical Significance
Low ejection fraction (≤25%)	3.5	Strongest predictor of mortality
Hyponatremia (<135 mEq/L)	2.8	Marker of neurohormonal activation
Elevated BNP (>1000 pg/mL)	2.5	Reflects ventricular wall stress
Renal impairment (Cr >1.5 mg/dL)	2.3	Cardiorenal syndrome marker
Advanced age (>75 years)	2.1	Comorbidities, frailty

Long-term Outcomes:

Parameter	1-Year	5-Year	10-Year
Overall Survival	75-80%	50%	25-30%
HF Hospitalization-free	60-65%	30-35%	15-20%
NYHA Class Improvement	40-50%	25-30%	15-20%

Advanced Therapies

Indications for Advanced Care:

Therapy	Indications	Survival Benefit	Quality of Life
Heart Transplantation	Stage D HF, age <65, no comorbidities	85% 1-year, 70% 5-year	Significant improvement
LVAD (Destination)	Inotrope-dependent, transplant ineligible	80% 1-year, 60% 2-year	Moderate improvement
Palliative Care	Symptom burden, advanced age, comorbidities	Comfort-focused	Symptom control

End-of-Life Considerations: Discuss advance directives early, consider palliative care referral for NYHA IV symptoms, address symptom burden (dyspnea, pain, fatigue), and provide psychosocial support for patients and families.